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ABSTRACT:
Uveal melanoma is the most common primary intraocular malignancy in adults, 
with a very high mortality rate due to frequent liver metastases. Consequently, the 
therapy of uveal melanoma remains a major clinical challenge and new treatment 
approaches are needed. For improving diagnosis and designing a rational and effective 
therapy, it is essential to elucidate molecular characteristics of this malignancy. The 
aim of this study therefore was to evaluate as a potential therapeutic target the 
expression of luteinizing hormone-releasing hormone (LHRH) receptor in human 
uveal melanoma. The expression of LHRH ligand and LHRH receptor transcript forms 
was studied in 39 human uveal melanoma specimens by RT-PCR using gene specific 
primers. The binding charachteristics of receptors for LHRH on 10 samples were 
determined by ligand competition assays. The presence of LHRH receptor protein 
was further evaluated by immunohistochemistry. The expression of mRNA for type I 
LHRH receptor was detected in 18 of 39 (46%) of tissue specimens. mRNA for LHRH-I 
ligand could be detected in 27 of 39 (69%) of the samples. Seven of 10 samples 
investigated showed high affinity LHRH-I receptors. The specific presence of full 
length LHRH receptor protein was further confirmed by immunohistochemistry. A high 
percentage of uveal melanomas express mRNA and protein for type-I LHRH receptors. 
Our results support the merit of further investigation of LHRH receptors in human 
ophthalmological tumors. Since diverse analogs of LHRH are in clinical trials or are 
already used for the treatment of various cancers, these analogs could be considered 
for the LHRH receptor-based treatment of uveal melanoma.  
INTRODUCTION
Although uveal melanoma is very rare, it is the 
most common primary intraocular malignancy in adults. 
Its incidence in the Western world seems to be relatively 
stable with about 7 new cases per year per 1 million 
individual. About half of the patients already have 
metastatic disease by the time of diagnosis. The outcome 
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of these is almost invariably fatal and death usually occurs 
within a year of the onset of systemic symptoms. [1,2] 
Treatment by systemic or intra-hepatic chemotherapy 
or partial hepatectomy only rarely prolongs the survival 
[3], emphasizing the need to develop more efficacious 
therapies. Recent progress in our understanding of the 
molecular processes underlying uveal melanoma should 
enable us to advance the diagnosis, prognosis and 
treatment of this malignancy. 
The discovery of specific receptors for peptide 
hormones on cancer cells has led to the development 
of cytotoxic and radiolabeled hormone analogs that are 
useful for tumor localization and targeted therapy. Various 
preclinical studies have shown that chemotherapy based 
on cytotoxic peptide conjugates targeted to receptors on 
tumors can improve the effectiveness of treatment and 
reduce general side effects. [4]
The presence of different isoforms of Luteinizing 
Hormone-Releasing Hormone (LHRH)  also known as 
Gonadotropin Hormone-Releasing Hormone has been 
identified in vertebrates. LHRH is the primary link 
between the brain and the pituitary in the regulation of 
gonadal function and plays a pivotal role in vertebrate 
reproduction. The actions of LHRH are mediated by 
high affinity receptors for  LHRH. The discovery of 
LHRH has had a major impact in medicine and has led 
to a variety of clinical uses of LHRH analogs in oncology 
and gynecology. [5]  Recently, it has been shown that 
various cancer cell lines, including cutaneous melanoma, 
xenografted into nude mice, can be inhibited by the 
targeted cytotoxic LHRH analog AN-152 (AEZS-108). 
[6] Since both cutaneous melanoma and uveal melanoma 
have the same neuroectodermal origin, but the presence 
of LHRH receptors has never been studied in uveal 
melanoma, we investigated the expression of mRNAs 
for LHRH-I ligand and for type I LHRH receptor in 
specimens of human uveal melanoma. The presence and 
binding characteristics of LHRH receptor protein were 
also examined.
RESULTS
Expression of human type-I LHRH receptors in 
human uveal melanoma
Our specimens of uveal melanoma tissue consisted 
of 11 epithelioid, 21 spindle and 7 mixed cell type tumors. 
The tumor thickness range was 6-12.9 mm according to 
ultrasonography. The tumor basal diameters as measured 
with ultrasonography, ranged from 9-19 mm. If the 
tumor thickness was more than 8 mm and/or the largest 
tumor diameter was more than 13 mm, we enucleated 
the eye without prior treatment. In those cases where 
the thickness was less than 8 mm or the basal diameter 
was less than 13 mm, but the tumor was growing in spite 
of the previous transpupillary thermotherapy and/or 
Ruthenium-106 plaque brachytherapy, enucleation was 
performed. Based on our recent knowledge, type I LHRH 
receptor has two splice variants, but only the full length 
receptor is functional. Our primer set for LHRH receptor 
was designed to specifically amplify the mRNA of the 
full length receptor, but to give no signals for the splice 
variants. We used LHRH receptor primers encompassing 
the open reading frame from exon 2 to exon 3, overlapping 
the missing part in the above mentioned two isoforms. 
The predicted size of the PCR amplified cDNA for 
type I LHRH receptor was 241 bp. Fourty six percent 
of our samples expressed receptors for type I LHRH 
receptor (Fig. 1., Table 1.). Among epithelioid type uveal 
melanomas, 6 of 11 (55 %) were found to be positive 
for the expression of LHRH receptor while spindle type 
melanomas included 10 of 21 (48%) positive samples. 
In the mixed cell type group (containing both epithelioid 
and spindle cells, with no dominant pattern), 2 of 7 (29%) 
of the tumors expressed type I LHRH receptor. The 
presence of full length LHRH-I receptor was confirmed 
by immunohistochemistry and correlated well with the 
findings by RT-PCR (Fig. 2.).  Among the specimens of 
RT-PCR positive uveal melanoma, the majority stained 
positive for LHRH receptors which could be detected in 
the form of red granules.
The presence of specific LHRH binding sites and 
characteristics of binding of [125I][D-Trp6]LHRH to 
membrane receptors on human uveal melanoma tissue 
was determined using ligand competition assays. Of 
the 10 specimens examined, 7 showed LHRH receptor 
binding (Table 2.). Analyses of the typical displacement of 
radiolabeled [D-Trp6]LHRH by the same unlabeled peptide 
revealed that the one-site model provided the best fit, 
indicating the presence of one class of high-affinity LHRH 
receptors in crude membranes derived from human uveal 
melanoma specimens. The computerized nonlinear curve-
fitting and the Scatchard plot analyses of the binding data 
in the 7 receptor-positive tumor specimens indicated that 
the single class of binding sites had a mean dissociation 
Figure 1: mRNA expression of LHRH-I (left panel) 
and its type I receptor (right panel) in the same tissue 
specimen set. L: 50 bp DNA-ladder (Fermentas); +: positive 
control (human pituitary); -: no template control; No. 1-5: 
representative human uveal melanoma tissues.
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Table 1: Clinicopathological characteristics and RT-PCR results of enucleated uveal melanoma 
samples
Number of patient Age at enucleation Sex Histology Earlier therapy Eye LHRH-R LHRH ligand
1. 64 M Spindle - L + +
2. 39 M Epithelioid Brachytherapy R + -
3. 70 M Spindle - R - +
4. 80 F Epithelioid - R + -
5. 47 M Epithelioid - L - -
6. 65 M Spindle - R + -
7. 76 M Spindle - R + +
8. 75 F Spindle - L - +
9. 84 F Spindle Brachytherapy L + +
10. 39 M Mixed - R - +
11. 35 M Spindle - L - -
12. 30 F Spindle - L + +
13. 44 F Spinde - L - +
14. 68 F Spindle - L - +
15. 76 M Spindle - R + +
16. 79 F Mixed - L - +
17. 79 F Epithelioid - R + +
18. 67 M Epithelioid Brachytherapy, TTT L + +
19. 60 M Epithelioid Brachytherapy (3x) R + +
20. 51 M Spindle - L - +
21. 66 M Epithelioid - R + +
22. 72 F Epithelioid - L - +
23. 76 M Spindle - L + +
24. 55 M Spindle - L - +
25. 54 M Epithelioid - R - +
26. 75 F Spindle - L + +
27. 64 F Epithelioid - R - +
28. 61 M Spindle - L - +
29. 50 F Spindle - R + -
30. 76 M Mixed - L + +
31. 38 M Spindle - R - +
32. 79 F Mixed - R - -
33. 53 M Epithelioid - R - +
34. 52 M Mixed - L - +
35. 45 M Mixed - R + -
36. 70 M Spindle - R + -
37. 43 M Spindle - L - -
38. 53 M Mixed - L - -
39. 51 M Spindle Brachytherapy (3x) L - -
L: left, R: right, TTT: Transpupillary Thermotherapy
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constant (Kd) of 3.69 nM (range, 1.35 to 6.36 nM) with 
a mean maximal binding capacity (Bmax) of 384.5 fmol/
mg of membrane protein (range, 251.5 to 511.6 fmol/mg 
protein). Biochemical parameters essential to establish 
the identity of specific binding sites were also determined. 
Thus the binding of [125I][D-Trp6] LHRH was found to be 
reversible, time- and temperature-dependent, and linear 
with protein concentration in the human uveal melanoma 
specimens examined (data not shown).  The specificity of 
LHRH binding was demonstrated by competitive binding 
experiments using several peptides structurally related or 
unrelated to LHRH (data not shown). 
The expression of mRNA for LHRH receptors was 
accompanied by ligand binding in all samples examined. 
Three of 10 tumor specimens did not exhibit mRNA 
expression for type I LHRH receptors, or show ligand 
binding; conversely, all receptor-positive specimens 
expressed a detectable amount of the receptor gene (Table 
2.). There was no evident correlation between receptor 
binding characteristics or mRNA expression and clinical 
and pathological findings.
Expression of mRNA for human type I LHRH in 
human uveal melanoma
In addition to the expression of type-I LHRH 
receptor, we also studied the presence of LHRH ligand 
in our uveal melanoma samples. The majority of uveal 
melanomas (27 of 39, 69%) showed marked expression of 
mRNA for LHRH-I ligand (Table 1.). The expected size 
of the PCR product of 245 bp could be detected in 8 of 
11 (73% ) of epithelioid and 15 of 21 (71%) of spindle 
type tumors. In the mixed tumor type, 4 of 7 (57%) 
expressed LHRH-I  (Fig. 1.). In 12 tumors (31%), both 
LHRH-I ligand and receptor were expressed. In 6 samples, 
only type I LHRH receptors were present, while in 15 
melanomas only LHRH-I ligand was present (Tabel 1.). 
Statistical analysis showed an association between 
age and LHRH receptor mRNA and ligand co-expression 
(p=0.0407): a 10-year increase of age meant an estimated 
87% increase in the odds of co-expression (OR=1.867, 
95%CI 1.027 to 3.393). Otherwise, there were no 
correlations between LHRH-I ligand or receptor mRNA 
expression and tumor subtype or clinical parameters. The 
clinicopathological characteristics of patients with uveal 
melanoma and the result of mRNA expression analysis are 
summarized in Table 1. 
Figure 2: Expression of LHRH receptor protein in 
enucleated human uveal melanoma tissue samples 
demonstrated by  immunoperoxidase staining. A, 
Hematoxylin-eosin stained section of a representative sample 
shows melanin-producing neoplastic cells with spindle and 
epithelioid pattern. a-d, images of representative samples 
immunostained for type I LHRH receptor; B, tumor sample 
without detectable mRNA for type I LHRH receptor also 
revealed no identifiable LHRH receptor protein using IHC 
staining; C, representative tissue section shows mild positivity 
for type I LHRH receptor (faint red cytoplasms of tumor cells). 
Insert is a negative control for the staining-specificity (see 
Methods); D, representative tumor sample exhibits intense 
expression of type I LHRH receptor in nearly 100% of tumor 
cells (intense red cytoplasmic staining) which correlated with 
the corresponding mRNA levels. Original magnifications of 
all images: 40x. Images B-D are immunoperoxidase stained 
sections with hematoxylin nuclear counterstaining.
Table 2: Expression of mRNA and binding 
characteristics of type I receptors for LHRH 
(LHRH-R) in 10 human uveal melanoma 
specimens.
Patient 
No.
LHRH-R
mRNA
Bmax
(fmol/mg protein) Kd (nM)
4. + 294.6 1.35
6. + 398.7 1.37
9. + 264.7 3.73
11. - - -
12. + 495.7 6.03
15. + 251.5 4.81
20. - - -
24. - - -
30. + 511.6 6.36
35. + 474.7 2.18
Oncotarget 2013; 4:1725www.impactjournals.com/oncotarget
DISCUSSION
Patients with uveal melanoma face a dismal 
prognosis as eventually about 45% of them die of 
metastasis, regardless of the fact that the tumor is most 
often diagnosed and locally cured before any signs of 
clinical disseminated disease appear. [7] This gave rise 
to the theory that micrometastases are already present 
early in the disease process, but remain dormant for years 
before a clinically detectable macrometastasis develops. 
[8] Most small and medium-sized uveal melanomas are 
currently managed by different forms of radiotherapy 
and local resection. However, it remains unclear what 
effect this treatment has on patient survival. Systemic 
treatment options for uveal melanoma are very limited. 
Adjuvant systemic therapy is mainly used in patients at 
high-risk of metastasis or in patients who have already 
developed metastasis, but the response rates to classical 
chemotherapeutic agents remain as low as 7%–25%. [9] 
Despite the improvements in diagnosis and therapy of 
primary uveal melanoma in the last 20–30 years, there 
has been no significant decrease in metastasis-related 
deaths. [10,11] Thus, the development of new therapeutic 
modalities is mandated. 
The presence of receptors for LHRH in various 
cancers and cancer cell lines originating from organs 
other than those of the reproductive system has been 
demonstrated by several authors. [6,12-15] It was 
suggested that the signal-transduction mechanisms 
mediated by type I of LHRH receptor are different in 
the pituitary and in cancer cells. [16,17]  It appears that 
in cancer cells LHRH analogs interfere with mitogenic 
signal transduction of growth-factor receptors and related 
oncogene products associated with activities of tyrosine 
kinases. [17,18]  It has been shown that cutaneous 
melanomas also express receptors for LHRH. [6,13] 
The treatment of melanoma cells by agonists of LHRH 
or cytotoxic analogs of LHRH significantly inhibits cell 
proliferation. [6,13] As uveal melanoma and melanoma of 
the skin are both of neural crest origin and share certain 
genetic characteristics, we analyzed the expression of 
LHRH receptors in uveal melanoma by RT-PCR, ligand 
competition assay and immunohistochemistry. As only 
the full length type I LHRH receptor is functional, our 
primer set was designed to selectively amplify receptor 
mRNA encoding the full length type I LHRH receptor 
but not its known splice variants. The antibody used 
for immunohistochemistry was also chosen to detect 
full length protein. In our present study, we found 
that 47% of our samples expressed type I receptors for 
LHRH. Furthermore, using ligand competition assay we 
examined the binding of [125I][D-Trp6]LHRH to membrane 
preparations of 10 uveal melanoma specimens. We 
found that 70% of the human uveal melanoma samples 
investigated possessed specific type I LHRH receptors 
with a mean Kd of 3.69 nM and with a mean Bmax of 
384.5  fmol/mg membrane protein. It is also important 
to note that all receptor-positive specimens expressed a 
detectable amount of the receptor gene. The receptor 
protein encoded by mRNA for type I LHRH receptors 
was also demonstrated by immunohistochemistry in tumor 
specimens.
The high incidence of positivity for type I LHRH 
receptor in uveal melanoma suggests that this tumor type 
might be a good candidate for therapy with LHRH analogs 
including the targeted cytotoxic peptide, AN-152 (AEZS-
108). AN-152 is already in phase III clinical trials in 
women with endometrial and ovarian cancers [18-20] and 
in phase I/II trials in men with castration resistant prostate 
cancer [21, Liu S, Schally AV, Dorff TB, Tsao-Wei DD, 
Groshen SG, Xiong S, Hawes D, Quinn DI, Tai YC, 
Block NL, Engel J, Pinski JK. A phase I/II trial of AN-
152, a targeted cytotoxic LHRH analog, in castration- and 
taxane-resistant prostate cancer. ASCO Annual Meeting 
June 3-7, 2011, Chicago, Abstract #74003] and patients 
with urothelial carcinoma [Fernandez GL, Schally AV, 
Koru-Sengul T, Merchan JR, Flores AM, Jorda M,  Datar 
R, Benedetto PW, Singal R, Block NL, Engel J. A phase 
I/II trial of AEZS-108 in locally advanced unresectable 
or metastatic luteinizing hormone-releasing hormone 
(LHRH) positive urothelial carcinoma (UC) patients 
who failed platinum based chemotherapy. ASCO Annual 
Meeting June 3-7, 2011 Chicago, Abstract # 83230]. 
Targeted therapy with cytotoxic peptide analogs consisting 
of a peptide molecule conjugated to a cytotoxic moiety 
such as doxorubicin, should be more effective and less 
toxic than conventional systemic chemotherapy [20,22]. 
Their only side effect appears to be myelosuppression 
caused by the occasional chemical cleavage of the 
cytotoxic radical doxorubicin. [4,5,18-20,22] The 
substantial expression of LHRH-I ligand (69%) and 
frequent co-expression of its receptor (31%) in our sample 
set may be indicative of the presence of an autocrine/
paracrine regulatory system based on LHRH in uveal 
melanoma. The regulation of several proteins associated 
with cell proliferation and cell motility is mediated by 
type I LHRH receptor/LHRH-I system, suggesting their 
important role in metastasis formation. [23] However, the 
role of this high expression of LHRH found by us is not 
clear. 
To the best of our knowledge, our findings represent 
the first identification of LHRH and its receptors in human 
uveal melanoma. Since the therapy for this malignancy 
is not adequate, our work may help to identify specific 
molecular targets for the prevention of metastasis or 
further proliferation of already disseminated metastases. 
Our findings that a high percentage of human uveal 
melanoma specimens express receptors for LHRH support 
the view that targeted cytotoxic LHRH analogs such as 
AN-152 could be used for an effective treatment of uveal 
melanoma.
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METHODS
Patients and Tissue Samples 
Human uveal melanoma specimens were obtained 
from 39 patients, 30-84 years of age at the time of 
enucleation, at the Department of Ophthalmology, 
University of Debrecen, Hungary. Normal pituitary 
samples (anterior lobe) were collected at autopsy at the 
Department of Pathology, University of Debrecen and 
were used as positive controls. After surgical removal, 
selected portions of the melanoma tissues were flash 
frozen and stored at -70°C. Histopathological examination 
of each specimen was undertaken to confirm the diagnosis. 
The local Institutional Ethics Committee approved the 
collection and use of these specimens for the current study 
and informed consent was obtained from these patients.  
RNA isolation, Reverse transcription and RT-
PCR
Total RNA was isolated using AllPrep DNA/
RNA/Protein Mini kit according to the manufacturer’s 
instructions (Qiagen, Hilden, Germany). Two 
hundred fifty nanograms of RNA from each sample 
were reverse transcribed into cDNA by QuantiTect 
Reverse Transcription kit (Qiagen) in a final volume 
of 20 µl. Two primer sets were designed to evaluate 
the expression of type I LHRH receptors (sense: 
5’-GGTGGCATCAAGCATTTTAT-3’, antisense: 5’–
ACATAGTAGGGAGTCCAGCAGACA-3’) and LHRH 
ligand (sense: 5’–GGCCTTATTCTACTGACTTGG-3’, 
antisense: 5’-TCTTCTGCCCAGTTTCCTCT-3’). As 
internal control, β-actin housekeeping gene (sense: 
5’-GGCATCCTCACCCTGAAGTA-3’, antisense 
5’-GGGGTGTTGAAGGTCTCAAA-3’) was used. In 
all PCR reactions, 1 µl of cDNA was amplified in a 25 
µl solution containing 1.5 mM MgCl2, 1x PCR buffer 
(Fermentas GmbH, St. Leon-Rot, Germany), 0.3 mM of 
each deoxynucleotide (Promega, Madison, WI), 1 unit of 
TrueStart HotStart DNA polymerase (Fermentas) and 0.25 
µM of each primer. Samples were denatured for 3 min at 
95°C, then subjected to 40 cycles at 95°C for 45 s, 59°C 
for 30 s, then 72°C for 1.5 min with a final extension at 
72°C for 10 min. Ten µl of each amplification reaction 
was then electrophoretically separated on 1.5% agarose 
gel, stained with ethidium bromide, and visualized under 
UV light.
Preparation of membranes and radioligand 
binding studies
Preparation of membranes for receptor studies 
was performed as described previously. [24] Briefly, the 
samples were thawed, cleaned, and then homogenized 
in 50 mM Tris-HCl buffer (pH 7.4), supplemented with 
protease inhibitors (0.25mM Phenylmethylsulfonyl 
Fluoride, 0.4% (v/v) Aprotinin and 2 µg/ml Pepstatin 
A) using an Ultra-Turrax tissue homogenizer (IKA 
Works, Wilmington, NC) on ice.  The homogenate was 
centrifuged at 500x g for 10 minutes at 4 ºC to remove 
nuclear debris and lipid layer.  The supernatant containing 
the crude membrane fraction was ultracentrifuged 
(Beckman L8-80 M) twice at 70,000x g for 50 minutes at 
4 ºC after resuspending in fresh buffer. The final pellet was 
resuspended in homogenization buffer and stored at -80 
ºC until assayed. Protein concentration was determined by 
the method of Bradford using a Bio-Rad protein assay kit 
(Bio-Rad Laboratories, Hercules, CA).
Radio-iodinated derivatives of [D-Trp6]LHRH 
were prepared by the chloramine-T method and purified 
by reverse-phase HPLC in our laboratory. [24] LHRH 
receptor binding assays were carried out as reported [24] 
using in vitro ligand competition assays based on binding 
of [125I][D-Trp6]LHRH as radioligand to uveal melanoma 
membrane fractions. This radioligand has been well-
characterized previously and shows high-affinity binding 
to human and rat pituitaries as well as human breast, 
prostate, and other cancers. [4-6,22,24] In brief, membrane 
homogenates containing 50-160 µg protein were incubated 
in duplicate or triplicate with 60-80,000 cpm [125I][D-Trp6]
LHRH and increasing concentrations (10-12 - 10-6 M) of 
nonradioactive peptides as competitors in a total volume 
of 150 µl of binding buffer. At the end of the incubation, 
125 µl aliquots of suspension were transferred onto the 
top of 1 ml of ice-cold binding buffer containing 1.5% 
bovine serum albumin in siliconized polypropylene 
microcentrifuge tubes (Sigma-Aldrich GmbH, Munich, 
Germany). The tubes were then centrifuged at 12,000x g 
for 3 minutes at 4 ºC (Beckman J2-21M).  Supernatants 
were aspirated and the bottoms of the tubes containing 
the pellet were cut off and counted in a gamma counter 
(Micromedic System, Huntsville, AL). Preliminary 
experiments were performed with membrane protein 
concentrations ranging from 20-250 µg/tube in order 
to determine the minimal amount of protein required to 
assess specific binding at a satisfactory level.  Our work 
showed that accurate results can be obtained over a range 
of 40-180 µg of membrane protein in an incubation 
volume of 150 µl.
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Immunohistochemistry (IHC)
Formalin-fixed paraffin-embedded tissue samples 
from enucleation were immunostained as described 
earlier. [24] Briefly, following antigen-retrieving (pH: 
6.0) and endogenous peroxidase-block, 3 μm thick 
sections were incubated with monoclonal antibody to 
LHRH-RI (NCL-GnRHR A9E4; Novocastra Laboratories 
Ltd., UK) at room temperature for 1 hour. After rinsing 3 
times in phosphate-buffered saline (PBS; pH:7.4, 5 mins 
each), sections were treated with anti-mouse IgG (Fab)2-
coupled to horse-radish-peroxidase (HRP) of EnVision+-
HRP detection kit using amino-ethyl-carbasol (AEC; red; 
Vector Labs, UK) peroxidase substrate according to the 
manufacturer’s instructions.  The use of red chromogenic 
substrate avoided the color-interference between the 
brown melanin pigments of melanomas and the positive 
staining of IHC. Human pituitary glands (anterior lobe) 
obtained from autopsy were used as positive controls. 
Negative controls in which primary antibody was replaced 
by normal serum were also included for each IHC-run.  
Statistical analysis
Variables were described using standard statistics. 
Association between categorical variables were assessed 
using Fisher’s exact tests, while those between continuous 
explanatory variables and binary outcomes were assessed 
using logistic regression, and expressed in terms of odds 
ratio (OR) and 95% confidence intervals (CI).
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